• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[抗人IV型胶原单克隆抗体的制备及其在IgA肾病中的应用]

[Monoclonal antibodies against human type IV collagen: preparation and its application in IgA nephropathy].

作者信息

Yu L

出版信息

Zhonghua Yi Xue Za Zhi. 1990 Apr;70(4):205-7, 16.

PMID:2167758
Abstract

In the present experiment, BALB/C mice were immunized with type IV collagen from human placenta, afterwards the mouse spleen cells were fused with mouse myeloma line P3 U1. As a result 4 hybridoma cell lines secreting monoclonal antibody against type IV collagen were developed successfully. McAb produced was verified to be isotype of IgG1 and unique as their specificity and purity are concerned. On Western blotting it bound to 120 KD, 95 KD and 60 KD of alpha 1 chain fragments of collagen IV. IF studies of renal biopsy specimen from 38 IgA nephropathy patient were made using this McAb to testify its characterization. Interestingly, it was found that its deposition within glomeruli corresponded to the distribution of collagen IV in general, but varied a great deal in different cases, depending on the presence, severity and extent of mesangial proliferation, sclerosis, crescent formation and tubulo-interstitial lesion. This fact might reflect that collagen IV contents of renal glomeruli in IgA nephropathy patients have developed certain changes either qualitatively or quantitatively, and it might serve as a marker to predict the severity and prognosis of this disease.

摘要

在本实验中,用来自人胎盘的IV型胶原免疫BALB/C小鼠,随后将小鼠脾细胞与小鼠骨髓瘤细胞系P3 U1融合。结果成功建立了4株分泌抗IV型胶原单克隆抗体的杂交瘤细胞系。所产生的单克隆抗体经鉴定为IgG1亚型,就其特异性和纯度而言具有独特性。在蛋白质印迹法中,它与IV型胶原α1链片段的120 KD、95 KD和60 KD条带结合。使用该单克隆抗体对38例IgA肾病患者的肾活检标本进行免疫荧光研究以证实其特性。有趣的是,发现其在肾小球内的沉积总体上与IV型胶原的分布相对应,但在不同病例中差异很大,这取决于系膜增生、硬化、新月体形成和肾小管间质病变的存在、严重程度和范围。这一事实可能反映出IgA肾病患者肾小球中IV型胶原的含量在质或量上已发生了某些变化,并且它可能作为预测该疾病严重程度和预后的一个标志物。

相似文献

1
[Monoclonal antibodies against human type IV collagen: preparation and its application in IgA nephropathy].[抗人IV型胶原单克隆抗体的制备及其在IgA肾病中的应用]
Zhonghua Yi Xue Za Zhi. 1990 Apr;70(4):205-7, 16.
2
[Monoclonal antibody against laminin a and b chains: preparation and its clinical application].
Zhonghua Nei Ke Za Zhi. 1990 Jul;29(7):425-7, 445.
3
Immunohistological localization of the novel epitope related to type IV collagen in normal and diseased renal tissues.新型IV型胶原相关表位在正常及病变肾组织中的免疫组织学定位
J Pathol. 1995 Dec;177(4):407-13. doi: 10.1002/path.1711770412.
4
Methods in laboratory investigation. Monoclonal antibodies to type IV collagen: probes for the study of structure and function of basement membranes.实验室研究方法。抗IV型胶原单克隆抗体:用于研究基底膜结构与功能的探针。
Lab Invest. 1983 May;48(5):639-49.
5
[Different expressions of alpha 2 (IV) and alpha 3 (IV) collagen mRNAs in renal glomeruli of IgA nephropathy].[α2(IV)和α3(IV)胶原蛋白mRNA在IgA肾病肾小球中的不同表达]
Zhonghua Yi Xue Za Zhi. 1995 Apr;75(4):197-200, 253.
6
Monoclonal antibodies against the Fc fragment of IgA alpha-chain: preparation and clinical application.
Biochem Mol Biol Int. 1994 Oct;34(3):587-94.
7
Monoclonal antibody to human basement membrane collagen type IV.抗人IV型基底膜胶原蛋白单克隆抗体。
Immunology. 1982 Sep;47(1):133-40.
8
[A new monoclonal antibody against human tubular brush border: preparation and its application in membranous nephropathy].
Zhonghua Nei Ke Za Zhi. 1990 Mar;29(3):149-51, 189.
9
Immunofluorescent studies on IgA nephropathy: type IV collagen and glomerular basement membrane component detected by Goodpasture's syndrome serum and laminin.IgA肾病的免疫荧光研究:用Goodpasture综合征血清及层粘连蛋白检测IV型胶原和肾小球基底膜成分
Tokai J Exp Clin Med. 1988 Aug;13(3):137-43.
10
Staphylococcus aureus antigens induce IgA-type glomerulonephritis in Balb/c mice.金黄色葡萄球菌抗原可诱导Balb/c小鼠发生IgA型肾小球肾炎。
J Nephrol. 2004 Jul-Aug;17(4):504-11.